Phase II study of ionidamine in patients with metastatic breast cancer - An Eastern Cooperative Oncology Group study

H. Ian Robins*, Donna S. Neuberg, Al B. Benson, Kishan J. Pandya, Douglass C. Tormey

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.

Original languageEnglish (US)
Pages (from-to)397-399
Number of pages3
JournalInvestigational New Drugs
Volume8
Issue number4
DOIs
StatePublished - Nov 1 1990

Fingerprint

Breast Neoplasms
Pharmaceutical Preparations
lonidamine

Keywords

  • breast cancer
  • lonidamine

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Robins, H. Ian ; Neuberg, Donna S. ; Benson, Al B. ; Pandya, Kishan J. ; Tormey, Douglass C. / Phase II study of ionidamine in patients with metastatic breast cancer - An Eastern Cooperative Oncology Group study. In: Investigational New Drugs. 1990 ; Vol. 8, No. 4. pp. 397-399.
@article{7e7c084860cd47a09e7321eb83d6b536,
title = "Phase II study of ionidamine in patients with metastatic breast cancer - An Eastern Cooperative Oncology Group study",
abstract = "The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.",
keywords = "breast cancer, lonidamine",
author = "Robins, {H. Ian} and Neuberg, {Donna S.} and Benson, {Al B.} and Pandya, {Kishan J.} and Tormey, {Douglass C.}",
year = "1990",
month = "11",
day = "1",
doi = "10.1007/BF00198600",
language = "English (US)",
volume = "8",
pages = "397--399",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

Phase II study of ionidamine in patients with metastatic breast cancer - An Eastern Cooperative Oncology Group study. / Robins, H. Ian; Neuberg, Donna S.; Benson, Al B.; Pandya, Kishan J.; Tormey, Douglass C.

In: Investigational New Drugs, Vol. 8, No. 4, 01.11.1990, p. 397-399.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II study of ionidamine in patients with metastatic breast cancer - An Eastern Cooperative Oncology Group study

AU - Robins, H. Ian

AU - Neuberg, Donna S.

AU - Benson, Al B.

AU - Pandya, Kishan J.

AU - Tormey, Douglass C.

PY - 1990/11/1

Y1 - 1990/11/1

N2 - The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.

AB - The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.

KW - breast cancer

KW - lonidamine

UR - http://www.scopus.com/inward/record.url?scp=0025104186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025104186&partnerID=8YFLogxK

U2 - 10.1007/BF00198600

DO - 10.1007/BF00198600

M3 - Article

C2 - 2084074

AN - SCOPUS:0025104186

VL - 8

SP - 397

EP - 399

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -